RFG Advisory’s ProQR Therapeutics PRQR Stock Holding History

RFG Advisory’s Portfolio PRQR Stock Details PRQR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$119K	Buy	64,000 +45,000	+237%	+$74.1K	﹤0.01%	1098
2026 Q1	$30.8K	Sell	19,000 -11,000	-37%	-$18K	﹤0.01%	1036
2025 Q4	$60.6K	Hold	30,000	–	–	﹤0.01%	973
2025 Q3	$63.9K	Hold	30,000	–	–	﹤0.01%	949
2025 Q2	$61.2K	Hold	30,000	–	–	﹤0.01%	916
2025 Q1	$39.9K	Hold	30,000	–	–	﹤0.01%	849
2024 Q4	$79.5K	Sell	30,000 -12,000	-29%	-$38.1K	﹤0.01%	753
2024 Q3	$76.4K	Buy	42,000 +10,000	+31%	+$18.8K	﹤0.01%	727
2024 Q2	$53.1K	Hold	32,000	–	–	﹤0.01%	695
2024 Q1	$73.3K	Buy	+32,000	New	+$68.4K	﹤0.01%	707

Other funds holding PRQR

FSA

Franklin Street Advisors Chapel Hill, North Carolina $1.79B AUM 28.1% 1-Year Est. Return

FFA

Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

RFG Advisory's PRQR Position: Q2 2026 in Review

RFG Advisory increased its ProQR Therapeutics (PRQR) stake by 237% in Q2 2026, buying an estimated $74.1K and bringing the position to 64,000 shares worth $119K. The position accounts for ﹤0.01% of the portfolio, ranked #1098.

RFG Advisory first reported a position in PRQR in Q1 2024 and has held it in 10 quarters since. 3 funds tracked by Wall St. Rank hold PRQR as of Q2 2026.

RFG Advisory held 64,000 shares of ProQR Therapeutics worth $119K as of Q2 2026.
RFG Advisory bought 45,000 ProQR Therapeutics shares in Q2 2026, an estimated $74.1K.
ProQR Therapeutics made up ﹤0.01% of RFG Advisory's portfolio in Q2 2026, its #1098 holding.
RFG Advisory first reported a position in ProQR Therapeutics in Q1 2024 and has held it in 10 quarters since.
3 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q2 2026.

Based on RFG Advisory's 13F filing for Q2 2026, filed 15 Jul 2026.